Cart
sales@molnova.com
ClpB-IN-1
CAS No. 1453172-23-0
ClpB-IN-1( —— )
Catalog No. M36349 CAS No. 1453172-23-0
ClpB-IN-1 is a potential antimicrobial agent.ClpB-IN-1 is a potent ClpB inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 33 | In Stock |
|
| 5MG | 51 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 163 | In Stock |
|
| 50MG | 257 | In Stock |
|
| 100MG | 415 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 926 | In Stock |
|
| 1G | 1237 | In Stock |
|
Biological Information
-
Product NameClpB-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionClpB-IN-1 is a potential antimicrobial agent.ClpB-IN-1 is a potent ClpB inhibitor.
-
DescriptionClpB-IN-1 (compound 7) is a potent ClpB inhibitor. ClpB-IN-1 is a potential antibacterial agents.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1453172-23-0
-
Formula Weight302.37
-
Molecular FormulaC14H10N2O2S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5 mg/mL (16.54 mM; Ultrasonic (<60°C)
-
SMILESC=CCN1C(=S)S\C(C1=O)=C1/C(=O)Nc2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Martin I, et, al. Screening and evaluation of small organic molecules as ClpB inhibitors and potential antimicrobials. J Med Chem. 2013 Sep 26;56(18):7177-89.?
molnova catalog
related products
-
P516-0475
P516-0475 is a novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO (IC50=10 uM).
-
Lysostaphin
Lysostaphin is a potent antistaphylococcal compound that exhibits enzymatic activity through three distinct enzymes: glycylglycine endopeptidase, endo-β-N-acetyl glucosamidase, and N-acetyl muramyl-L-alanine amidase.
-
Murepavadin
Murepavadin (POL7080)?is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.
